Accepted Manuscript

Title: Understanding effect of formulation and manufacturing variables on the critical quality attributes of warfarin sodium product

Author: Ziyaur Rahman Maxwell Korang-Yeboah Akhtar Siddiqui Adil Mohammad Mansoor A. Khan

PII:	S0378-5173(15)30163-0
DOI:	http://dx.doi.org/doi:10.1016/j.ijpharm.2015.08.065
Reference:	IJP 15148
To appear in:	International Journal of Pharmaceutics
Received date:	26-6-2015
Revised date:	5-8-2015
Accepted date:	21-8-2015

Please cite this article as: Rahman, Ziyaur, Korang-Yeboah, Maxwell, Siddiqui, Akhtar, Mohammad, Adil, Khan, Mansoor A., Understanding effect of formulation and manufacturing variables on the critical quality attributes of warfarin sodium product.International Journal of Pharmaceutics http://dx.doi.org/10.1016/j.ijpharm.2015.08.065

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Understanding effect of formulation and manufacturing variables on the critical quality attributes of warfarin sodium product

Ziyaur Rahman, Maxwell Korang-Yeboah, Akhtar Siddiqui, Adil Mohammad, Mansoor A. Khan^{*}

Division of Product Quality and Research, Center for Drug Evaluation and Research, Food and Drug Administration, Maryland, USA.

*-Corresponding author

Mansoor A. Khan, R.Ph., Ph.D. FDA/CDER/DPQR White Oak, LS Building 64, Room 1070 10903 New Hampshire Ave Silver Spring, MD-20993-002 Phone-+1-301-796-0016 Email- Mansoor.Khan@fda.hhs.gov

Disclaimer - The views and opinions expressed in this paper are only those of the authors, and do not necessarily reflect the views or policies of the FDA.

ABSTRACT

Warfarin sodium (WS) is a narrow therapeutic index drug and its product quality should be thoroughly understood and monitored in order to avoid clinical performance issues. This study was focused on understanding the effect of manufacturing and formulation variables on WS product critical quality attributes (CQAs). Eight formulations were developed with lactose monohydrate (LM) or lactose anhydrous (LA), and were either wet granulated or directly Download English Version:

https://daneshyari.com/en/article/5818352

Download Persian Version:

https://daneshyari.com/article/5818352

Daneshyari.com